P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

Documenti analoghi

• P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
  di: Frederick Lansigan, et al.
  Pubblicazione: (2023-08-01)
• P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS
  di: A. R. Mato, et al.
  Pubblicazione: (2022-06-01)
• PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
  di: J. N. Allan, et al.
  Pubblicazione: (2022-06-01)
• A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
  di: Chaitra Ujjani, et al.
  Pubblicazione: (2018-04-01)
• Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
  di: Toby A. Eyre, et al.
  Pubblicazione: (2020-02-01)